These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 20089519)

  • 21. Plasma levels of apolipoproteins A-1 and B in Indian patients with angiographically defined coronary artery disease.
    Bahl VK; Vaswani M; Thatai D; Wasir HS
    Int J Cardiol; 1994 Sep; 46(2):143-9. PubMed ID: 7814163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum lipid profiles and the presence of yellow plaque in coronary lesions in vivo.
    Kitamura K; Mizuno K; Miyamoto A; Nakamura H
    Am J Cardiol; 1997 Mar; 79(5):676-9. PubMed ID: 9068533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of plasma fatty acid alteration with the severity of coronary artery disease lesions in Tunisian patients.
    Hadj Ahmed S; Kaoubaa N; Kharroubi W; Zarrouk A; Najjar MF; Batbout F; Gamra H; Lizard G; Hammami M
    Lipids Health Dis; 2017 Aug; 16(1):154. PubMed ID: 28806974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma oxidized low-density lipoprotein is an independent risk factor in young patients with coronary artery disease.
    Huang Y; Hu Y; Mai W; Cai X; Song Y; Wu Y; Dong Y; Huang H; He Z; Li W; Yang Y; Rao S
    Dis Markers; 2011; 31(5):295-301. PubMed ID: 22048271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apo B/Apo A-I ratio in central and peripheral arterial diseases.
    Lima LM; Carvalho Md; Sabino Ade P; Mota AP; Fernandes AP; Sousa MO
    Arq Bras Endocrinol Metabol; 2007 Oct; 51(7):1160-5. PubMed ID: 18157393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conventional and non-conventional coronary risk factors in male premature coronary artery disease patients already having a low Framingham risk score.
    Koz C; Baysan O; Hasimi A; Cihan M; Uzun M; Yokusoglu M; Sag C; Isik E
    Acta Cardiol; 2008 Oct; 63(5):623-8. PubMed ID: 19014007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy.
    Walldius G; Jungner I
    J Intern Med; 2004 Feb; 255(2):188-205. PubMed ID: 14746556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early coronary artery disease--Usual and unusual suspects.
    Markousis-Mavrogenis G; Mavrogeni S; Kolovou G
    Int J Cardiol; 2016 Jan; 202():511. PubMed ID: 26447655
    [No Abstract]   [Full Text] [Related]  

  • 29. Lipid profile in the acute phase of coronary artery disease.
    Batalla A; Reguero JR
    Int J Cardiol; 2001; 80(2-3):265. PubMed ID: 11676391
    [No Abstract]   [Full Text] [Related]  

  • 30. Correlates of atherosclerosis in coronary arteries of patients undergoing angiographic evaluation.
    Perez GO; Mendez AJ; Goldberg RB; Duncan R; Palomo A; DeMarchena E; Hsia SL
    Angiology; 1990 Jul; 41(7):525-32. PubMed ID: 2117860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipoproteins and the endothelium: past, present and future.
    Lee J; Leeson PC
    Hellenic J Cardiol; 2006; 47(3):158-9. PubMed ID: 16862823
    [No Abstract]   [Full Text] [Related]  

  • 32. Risk factors, risk prediction, and the apolipoprotein B-apolipoprotein A-I ratio.
    Berkwits M; Guallar E
    Ann Intern Med; 2007 May; 146(9):677-9. PubMed ID: 17470836
    [No Abstract]   [Full Text] [Related]  

  • 33. Lessons from coronary atherosclerosis "regression" trials.
    Waters D
    Cardiol Clin; 1996 Feb; 14(1):31-50. PubMed ID: 9072290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical use of apolipoprotein quantitation.
    Johnson AM; Craig WY; Ledue TB
    Ann Intern Med; 1995 Jan; 122(1):69; author reply 69-70. PubMed ID: 7985903
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical use of apolipoprotein quantitation.
    Justiniani FR
    Ann Intern Med; 1995 Jan; 122(1):69. PubMed ID: 7985901
    [No Abstract]   [Full Text] [Related]  

  • 36. SYNTAX Score in Patients With Stable Coronary Artery Disease.
    Ozbay MB; Ozen Y; Yayla Ç
    Angiology; 2019 Feb; 70(2):186. PubMed ID: 30037289
    [No Abstract]   [Full Text] [Related]  

  • 37. Is it time to measure apolipoprotein B?
    Sniderman AD; Silberberg J
    Arteriosclerosis; 1990; 10(5):665-7. PubMed ID: 2206112
    [No Abstract]   [Full Text] [Related]  

  • 38. LDL quality influences CAD progression.
    Fernandez-Ruiz I
    Nat Rev Cardiol; 2018 Oct; 15(10):582. PubMed ID: 30054572
    [No Abstract]   [Full Text] [Related]  

  • 39. Proteins and Clinical Mass Spectrometry: A Fairy Tale?
    van den Broek I
    Clin Chem; 2019 Feb; 65(2):220-221. PubMed ID: 30523200
    [No Abstract]   [Full Text] [Related]  

  • 40. Circulating lipid and lipoprotein profiles and their correlation to cardiac function and cardiovascular outcomes in patients with acute myocardial infarction.
    Wu H; Wang C; Tuerhongjiang G; Qiao X; Hua Y; She J; Yuan Z
    J Investig Med; 2021 Oct; 69(7):1310-1317. PubMed ID: 33972383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.